| References |
1. Mátyás C, Németh BT, Oláh A, Hidi L, Birtalan E, Kellermayer D, Ruppert M, Korkmaz-Icöz S, Kökény G, Horváth EM, Szabó G, Merkely B, Radovits T. The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol. 2015 Oct 31;14:145. doi: 10.1186/s12933-015-0309-x. PubMed PMID: 26520063; PubMed Central PMCID: PMC4628236. 2. Reinke Y, Gross S, Eckerle LG, Hertrich I, Busch M, Busch R, Riad A, Rauch BH, Stasch JP, Dörr M, Felix SB. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats. Eur J Pharmacol. 2015 Nov 15;767:1-9. doi: 10.1016/j.ejphar.2015.09.022. Epub 2015 Sep 25. PubMed PMID: 26407652. 3. Cosyns SM, Huyghe L, Thoonen R, Stasch JP, Brouckaert P, Lefebvre RA. Influence of cinaciguat on gastrointestinal motility in apo-sGC mice. Neurogastroenterol Motil. 2014 Nov;26(11):1573-85. doi: 10.1111/nmo.12424. Epub 2014 Sep 8. PubMed PMID: 25200007. 4. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J. 2013 Jan;34(1):57-67. doi: 10.1093/eurheartj/ehs196. Epub 2012 Jul 9. PubMed PMID: 22778174. |
